Non‐HDL cholesterol vs. Apo B for risk of coronary heart disease in healthy individuals: the EPIC‐Norfolk prospective population study

Sondermeijer, Brigitte M.; Rana, Jamal S.; Arsenault, Benoit J.; Shah, Prediman K.; Kastelein, John J.P.; Wareham, Nicholas J.; Boekholdt, S. Matthijs; Khaw, Kay‐Tee

doi:10.1111/eci.12129

Cited by 30Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsCholesterol and Lipid Metabolism

Non‐HDL cholesterol vs. Apo B for risk of coronary heart disease in healthy individuals: the EPIC‐Norfolk prospective population study

Sondermeijer, Brigitte M., Rana, Jamal S., Arsenault, Benoit J., Shah, Prediman K., Kastelein, John J.P., Wareham, Nicholas J., Boekholdt, S. Matthijs, Khaw, Kay‐Tee·2013·European Journal of Clinical Investigation

DOI 10.1111/eci.12129

Open this paper in CoChat — free account

Abstract

Background: There is an ongoing debate about the performance of non–high‐density lipoprotein cholesterol (non‐HDL‐C) compared with apolipoprotein B (apo B) in the prediction of coronary heart disease (CHD) risk. Therefore, we compared the associations between non‐HDL‐C and apo B in regard to CHD among apparently healthy Western E uropean individuals. Design: In the E uropean Prospective Investigation into Cancer and Nutrition (EPIC)‐Norfolk prospective population study, 25 639 men and women aged 45–79 years were followed for 11·4 ± 2·8 years. Those with diabetes or prevalent CHD at baseline were excluded. A total of 2066 (12·1%) participants developed CHD during 195 692 person‐years follow‐up. Results: The multivariable‐adjusted hazard ratio [HR] of future CHD per one standard deviation increase was 1·22 [95% confidence interval (CI): 1·17–1·27] for LDL‐C, 1·26 (95% CI 1·20–1·31) for non‐HDL‐C and 1·19 (95% CI 1·14–1·24) for apo B, respectively. The multivariable‐adjusted HR of future CHD in the highest quartile LDL‐C was 1·67 (95% CI: 1·47–1·91). For non‐HDL‐C and apo B, these respective HR s were 1·87 (95% CI: 1·62–2·15) and 1·56 (95% CI: 1·36–1·78). Kaplan–Meier survival analyses showed that there was incremental and comparable increase in risk of CHD with increasing quartiles of both non‐HDL‐C and apo B. Conclusions: In this prospective study, non‐HDL‐C and apo B were comparable in their ability to predict risk of future CHD.

Integrity signals

Registry

Crossref · 10.1111/eci.12129

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Apo B is more predictive of coronary heart disease risk than LDL-C.
“Apo B has also been shown to be more predictive of risk of coronary heart disease than LDL-C.39”
From Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial (2014) · cites this paper as [39]

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944 · see citing works
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
(2002) · Circulation · doi:10.1161/circ.106.25.3143 · Cited by 14,092 · see citing works
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198 · see citing works
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490 · see citing works
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467 · see citing works
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439 · see citing works
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848 · see citing works
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
Howard, W. J. (2007) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70063-5 · Cited by 6,672 · see citing works
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,638 · see citing works
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549 · see citing works
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489 · see citing works
Self-citation
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
Pedersen, T. R. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.027 · Cited by 3,098 · see citing works
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · see citing works
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731 · see citing works
Untitled work
Graham (2007) · doi:10.1097/01.hjr.0000277983.23934.c9 · Cited by 1,647 · see citing works
High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study
Walldius, G., Jungner, I., Holme, I., AASTVEIT, A. H., Kolar, W., & Steiner, E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07098-2 · Cited by 1,227 · see citing works
Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case–control study
McQueen, M. J., Hawken, S., Wang, X., Ounpuu, S., Sniderman, A., Probstfield, J., Steyn, K., Sanderson, J. E., Hasani, M., Volkova, E., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61076-4 · Cited by 864 · see citing works
Combined Impact of Health Behaviours and Mortality in Men and Women: The EPIC-Norfolk Prospective Population Study
Khaw, K.-T., Wareham, N., Bingham, S., Welch, A., Luben, R., & Day, N. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050012 · Cited by 840 · see citing works
Self-citation
EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer.
Day, N., Oakes, S., Luben, R., Khaw, K., Bingham, S., Welch, A., & Wareham, N. (1999) · Nature · doi:10.17863/cam.89388 · Cited by 780 · see citing works
Self-citation
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706 · see citing works
A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk
Sniderman, A. D., Williams, K., Contois, J. H., Monroe, H. M., McQueen, M. J., de Graaf, J., & Furberg, C. D. (2011) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.959247 · Cited by 659 · see citing works
High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study
Walldius, G., Jungner, I., Holme, I., AASTVEIT, A. H., Kolar, W., & Steiner, E. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00666-9 · Cited by 534 · see citing works
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment
Kastelein, J. J. P., van der Steeg, W. A., Holme, I., Gaffney, M., Cater, N. B., Barter, P., Deedwania, P., Olsson, A. G., Boekholdt, S. M., Demicco, D. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.713438 · Cited by 478 · see citing works
Meta-Analysis of the Relationship Between Non–High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk
Robinson, J. G., Wang, S., Smith, B. J., & Jacobson, T. A. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.024 · Cited by 368 · see citing works
Beyond Low-Density Lipoprotein Cholesterol
Arsenault, B. J., Rana, J. S., Stroes, E. S. G., Després, J.-P., Shah, P. K., Kastelein, J. J. P., Wareham, N. J., Boekholdt, S. M., & Khaw, K.-T. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.057 · Cited by 342 · see citing works
Self-citation
Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices
Contois, J. H., McConnell, J. P., Sethi, A. A., Csako, G., Devaraj, S., Hoefner, D. M., & Warnick, G. R. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.118356 · Cited by 326 · see citing works
Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women
Mora, S., Rifai, N., Buring, J. E., & Ridker, P. M. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.117929 · Cited by 176 · see citing works
Role of the Apolipoprotein B–Apolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A Case–Control Analysis in EPIC-Norfolk
van der Steeg, W. A., Boekholdt, S. M., Stein, E. A., El-Harchaoui, K., Stroes, E. S. G., Sandhu, M. S., Wareham, N. J., Jukema, J. W., Luben, R., Zwinderman, A. H., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-9-200705010-00007 · Cited by 165 · see citing works
Self-citation
Non–High-Density Lipoprotein Cholesterol Versus Apolipoprotein B in Cardiovascular Risk Stratification
Ramjee, V., Sperling, L. S., & Jacobson, T. A. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.05.009 · Cited by 157 · see citing works
The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls
Parish, S., Peto, R., Palmer, A. J., Clarke, R. T., Lewington, S., Offer, A. R., Whitlock, G., Clark, S., Youngman, L. D., Sleight, P., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp221 · Cited by 116 · see citing works
International Federation of Clinical Chemistry Standardization Project for Measurements of Apolipoproteins A-I and B. II. Evaluation and Selection of Candidate Reference Materials
Albers, J. J., Marcovina, S. M., & Kennedy, H. (1992) · Clinical Chemistry · doi:10.1093/clinchem/38.5.658 · Cited by 103 · see citing works
How to control residual cardiovascular risk despite statin treatment: Focusing on HDL–cholesterol
Lim, S. K., Park, Y. M., Sakuma, I., & Koh, K. K. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.03.127 · Cited by 64 · see citing works
Are You Targeting Non–High-Density Lipoprotein Cholesterol?
Robinson, J. G. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.056 · Cited by 44 · see citing works
To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B?
Lavie, C. J., Milani, R. V., & O’Keefe, J. H. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0058 · Cited by 24 · see citing works
Association between dyslipidemia and vascular events in patients treated with statins: Report from the UK General Practice Research Database
Sazonov, V., Beetsch, J. W., Phatak, H. M., Wentworth, C., & Evans, M. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.07.021 · Cited by 15 · see citing works
Should we change our lipid management strategies to focus on non-high-density lipoprotein cholesterol?
Rana, J. S., & Boekholdt, S. M. (2010) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32833f0365 · Cited by 11 · see citing works
Self-citation
Using Apolipoprotein B to Manage Dyslipidemia
Robinson, J. G. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0287 · Cited by 1 · see citing works

Flagged first, then by citations

Sorted by citations

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial
Kastelein, J. J. P., Maki, K. C., Susekov, A., Ezhov, M., Nordestgaard, B. G., Machielse, B. N., Kling, D., & Davidson, M. H. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.10.003 · Cited by 233 · see citing works
Self-citation
Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, triglycerides, and apolipoprotein B and cardiovascular risk in patients with manifest arterial disease
van den Berg, M. J., van der Graaf, Y., de Borst, G. J., Kappelle, L. J., Nathoe, H. M., Visseren, F. L. J., van Petersen, R., van Dinther, B. G. F., Algra, A., van der Graaf, Y., et al. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.06.048 · Cited by 39 · see citing works

Proposal for Setting Guidance Levels on Entrance Surface Doses for Radiographic Examinations on Children in Japan
Mori, T., Mutoh, H., Satoh, H., et al. (2002) · JAPANES JOURNAL OF MEDICAL INSTRUMENTATION · doi:10.4286/ikakikaigaku.72.2_65
Serum triglyceride levels and incidence of hypertension in a general Japanese population: ISSA-CKD study
Ishida, S., Kondo, S., Funakoshi, S., Abe, M., Satoh, A., Kawazoe, M., Maeda, T., Yoshimura, C., Nishida, Y., Tada, K., et al. (2023) · Hypertension Research · doi:10.1038/s41440-023-01175-4 · Cited by 8 · see citing works
The learning curve associated with the implantation of the Nanostim leadless pacemaker
and, O. B. O. T. L. I. I., Tjong, F. V. Y., Observational Study Investigators, et al. (2018) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-018-0438-8 · Cited by 18 · see citing works
Outcomes After Acute Ischemic Stroke in the United States: Does Residential ZIP Code Matter?
Agarwal, S., Menon, V., & Jaber, W. A. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001629 · Cited by 54 · see citing works
4–2 Serum C-peptide levels and breast cancer risk: Results from the European Prospective Investigation into Cancer and Nutrition (EPIC)
Vogel, V. G. (2007) · Breast Diseases A Year Book Quarterly · doi:10.1016/s1043-321x(07)80108-1 · Cited by 1 · see citing works

Authors: Sondermeijer, B. M., Rana, J. S., Arsenault, B. J., Shah, P. K., Kastelein, J. J. P., Wareham, N. J., Boekholdt, S. M., & Khaw, K.
Affiliations: Amsterdam UMC Location University of Amsterdam (NL)
Kaiser Permanente (US)
Department of Vascular Medicine Academic Medical Center Amsterdam The Netherlands
Cedars-Sinai Medical Center (US)
University of Cambridge (GB)
Corresponding author: Boekholdt, S. Matthijs
ORCID: Rana, Jamal S.
Shah, Prediman K.
Kastelein, John J.P.
Wareham, Nicholas J.
Boekholdt, S. Matthijs
Khaw, Kay‐Tee
Venue: European Journal of Clinical Investigation
Publisher: Wiley
Published: 2013-07-17
Volume: 43
Issue: 10
Pages: 1009-1015
ISSN: 0014-2972 (ISSN-L)
1365-2362
DOI: 10.1111/eci.12129
OpenAlex: W2000504745
Cited by: 30
References: 37
Citations by year: 2026: 2 · 2024: 2 · 2023: 3 · 2021: 1 · 2020: 1 · 2019: 3 · 2018: 4 · 2017: 4 · 2016: 2 · 2015: 2 · 2014: 5 · 2013: 1
FWCI: 3.28
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: European Journal of Clinical Investigation (publishedVersion)
PubMed (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Funders: European Society of Cardiology
Canadian Institutes of Health Research
Medical Research Council (MC_UU_12015/1)
Topics: Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
Keywords: non-HDL cholesterol, apolipoprotein B, coronary artery disease, cardiovascular risk prediction, LDL cholesterol, healthy adults, EPIC-Norfolk cohort
MeSH terms: Aged, Apolipoproteins B, Coronary Disease, England, Epidemiologic Methods, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Non‐HDL cholesterol vs. Apo B for risk of coronary heart disease in healthy individuals: the EPIC‐Norfolk prospective population study

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks